Literature DB >> 7286498

The role of "diabetogenic" hormones on carbohydrate and lipid metabolism following oral glucose loading in insulin dependent diabetics: effects of acute hormone administration.

P Bratusch-Marrain, W Waldhäusl, B Grubeck-Loebenstein, A Korn, H Vierhapper, P Nowotny.   

Abstract

To evaluate the relative role of "diabetogenic" hormones as insulin antagonists in severe derangements of diabetic control, glucagon, cortisol, growth hormone and adrenaline were administered by continuous intravenous infusion, separately and in combination, to ketosis-prone insulin-dependent diabetics (n = 11). The amount of insulin required for the assimilation of a 50 g glucose load during the various hormone infusions was determined by means of an automated glucose-controlled insulin infusion system and used as an index of insulin effectiveness. Raising plasma hormone concentrations acutely into the range seen in severe diabetic states (glucagon 517 +/- 70 pg/ml; cortisol 32 +/- 3 micrograms/dl; growth hormone 14 +/- 3 ng/ml) did not alter significantly blood glucose profile and insulin requirement (control 11.3 +/- 1.1 U; glucagon 11.6 +/- 2.0 U; cortisol 11.1 +/- 0.4 U; growth hormone 12.9 +/- 1.4 U), except for adrenaline (plasma level 550 +/- 192 pg/ml), which caused a marked rise in blood glucose levels and a threefold increase in insulin demand (31.1 +/- 3.7 U). Combined infusion of all hormones did not potentiate significantly the latter effect (38.3 +/- 4.7 U). The effectiveness of metabolic control by insulin was assessed by a marked decrease in plasma nonesterified free fatty acids and ketone bodies upon its administration after glucose ingestion in all groups studied. It is concluded that from the hormones investigated within this study adrenaline exerts the strongest diabetogenic action during its short term administration followed by that of growth hormone. Whereas it may well be that over-insulinization of the patients by the glucose controlled insulin infusion system has overcome and disguised the smaller diabetogenic effects of cortisol and glucagon.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286498     DOI: 10.1007/BF00252687

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  41 in total

1.  The diabetogenic action of somatostatin in healthy subjects and in maturity onset diabetics.

Authors:  W Waldhäusl; P Bratusch-Marrain; R Dudczak; E Deutsch
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

2.  Characterization of the glucagon response to hypoglycemia in man.

Authors:  J E Gerich; V Schneider; S E Dippe; M Langlois; C Noacco; J H Karam; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

3.  Human growth hormone as a regulator of blood glucose concentration and as a diabetogenic substance.

Authors:  R Luft; E Cerasi
Journal:  Diabetologia       Date:  1968-01       Impact factor: 10.122

4.  Metabolic homeostasis in juvenile diabetes mellitus. II. Increased ketone responsiveness to epinephrine.

Authors:  L Baker; R Kaye; N Haque
Journal:  Diabetes       Date:  1969-06       Impact factor: 9.461

5.  Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.

Authors:  R S Sherwin; M Fisher; R Hendler; P Felig
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

6.  Studies of diabetes mellitus: the relation of stressful life situations to the concentration of ketone bodies in the blood of diabetic and non-diabetic humans.

Authors:  L E HINKLE; G B CONGER; S WOLF
Journal:  J Clin Invest       Date:  1950-06       Impact factor: 14.808

7.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

8.  Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man.

Authors:  W Waldhäusl; P Bratusch-Marrain; S Gasic; A Korn; P Nowotny
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

9.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men.

Authors:  J E Liljenquist; J D Bomboy; S B Lewis; B C Sinclair-Smith; P W Felts; W W Lacy; O B Crofford; G W Liddle
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Lack of a role for glucagon in the disposal of an oral glucose load in normal man.

Authors:  J E Liljenquist; D Rabin
Journal:  J Clin Endocrinol Metab       Date:  1979-12       Impact factor: 5.958

View more
  5 in total

Review 1.  The physiological basis of insulin treatment--clinical aspects.

Authors:  W K Waldhäusl
Journal:  Diabetologia       Date:  1986-12       Impact factor: 10.122

Review 2.  Insulin-counteracting hormones: their impact on glucose metabolism.

Authors:  P R Bratusch-Marrain
Journal:  Diabetologia       Date:  1983-02       Impact factor: 10.122

3.  The 75-g oral glucose tolerance test: effect on splanchnic metabolism of substrates and pancreatic hormone release in healthy man.

Authors:  W K Waldhäusl; S Gasić; P Bratusch-Marrain; P Nowotny
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

4.  Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast.

Authors:  A J Francis; P D Home; I Hanning; K G Alberti; W M Tunbridge
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-09

Review 5.  Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.

Authors:  Utkarsh Ojha; Lenisse Reyes; Florence Eyenga; Diane Oumbe; Justyna Watkowska; Henock Saint-Jacques
Journal:  Am J Cardiovasc Drugs       Date:  2021-06-30       Impact factor: 3.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.